Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, is reducing its workforce by approximately 57 percent. The reduction is scheduled to be completed by March 31, 2023. The decision was made because Jounce believes advancement of its clinical programs, JTX-8064 and vopratelimab, requires funding and a scope that the company cannot pursue on its own and will be seeking business development op...